Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 13/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.41 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3471925 | 0.83 | SLC6A2 (0.43) | SLC6A2SLC6A4NOS2SLC6A3TACR1 | |
| SCHEMBL5188572 | 0.74 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1087321 | 0.74 | SLC6A4 (0.49) | SLC6A2SLC6A4NOS2NOS3NOS1 | |
| SCHEMBL15698421 | 0.73 | EP300 (0.35) | — | |
| SCHEMBL24379176 | 0.72 | SLC6A2 (0.34) | SLC6A2SLC6A4 | |
| SCHEMBL7114801 | 0.72 | NOS3 (0.34) | SLC6A2SLC6A4NOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL3472850 | 0.70 | NOS3 (0.33) | SLC6A2SLC6A4NOS2NOS3NOS1 | |
| SCHEMBL28797359 | 0.70 | SLC6A2 (0.38) | SLC6A2SLC6A4 | |
| SCHEMBL3429155 | 0.68 | — | — | |
| SCHEMBL5868706 | 0.67 | SLC6A2 (0.54) | SLC6A2SLC6A4NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100310477-A1 | Pharmaceutical compositions based on anticholingerics and additional active ingredients | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG. (DE) | 2010-12-09 | — | — | US | disclosed |
| US-7776315-B2 | Pharmaceutical compositions based on anticholinergics and additional active ingredients | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20050148562-A1 | Pharmaceutical compositions based on anticholinergics and additional active ingredients | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-07-07 | — | — | US | disclosed |
| US-20040151770-A1 | Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-08-05 | — | — | US | disclosed |
| US-6747044-B2 | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS; ANTIULCER AGENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-06-08 | — | — | US | disclosed |
| US-6696042-B2 | INHALATION AEROSOL COMPRISING TIOTROPIUM SALT AND PROPELLANT GAS; RESPIRATORY SYSTEM DISORDERS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-02-24 | — | — | US | disclosed |
| EP-1370293-A2 | NOVEL MEDICAMENT COMPOSITIONS BASED ON ANTICHOLINERGICS AND ON NK1 RECEPTOR ANTAGONISTS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2003-12-17 | — | — | EP | disclosed |
| US-20030212075-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND NK1-RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-11-13 | — | — | US | disclosed |
| US-6620438-B2 | Arylglycinamide derivatives | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-16 | — | — | US | disclosed |
| EP-1328516-A1 | NOVEL NEUROKININ ANTAGONISTS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | Boehringer Ingelheim Pharma KG (DE) | 2003-07-23 | — | — | EP | disclosed |
| US-20030100565-A1 | Method for the treatment or prevention of atopic dermatitis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-05-29 | — | — | US | disclosed |
| WO-2003026658-A1 | METHOD FOR THE TREATMENT OR PREVENTION OF ATOPIC DERMATITIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-04-03 | — | — | WO | disclosed |
| EP-1295599-A1 | Method for the treatment of prevention of atopic dermatitis | Boehringer Ingelheim International GmbH (DE) | 2003-03-26 | — | — | EP | disclosed |
| US-20020169181-A1 | Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-11-14 | — | — | US | disclosed |
| US-20020147219-A1 | Neurokinin antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-10-10 | — | — | US | disclosed |
| WO-2002069944-A2 | NOVEL MEDICAMENT COMPOSITIONS BASED ON ANTICHOLINERGICS AND ON NK1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002032865-A1 | NOVEL NEUROKININ ANTAGONISTS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148562-A1 | Pharmaceutical compositions based on anticholinergics and additional active ingredients | CHRM3, ADRA2C, PDE3A | SLC6A2 1044/4885SLC6A4 715/4885NOS2 1029/4885 |
| US-20040151770-A1 | Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists | TACR2, CHRM3, TACR1 | SLC6A2 730/4885SLC6A4 921/4885NOS2 2753/4885 |
| US-20020147219-A1 | Neurokinin antagonists | TACR2, TACR1, TAC3 | SLC6A2 669/4885SLC6A4 426/4885NOS2 2579/4885 |
| US-20100310477-A1 | Pharmaceutical compositions based on anticholingerics and additional active ingredients | PDE4B, CHRM3, ADRA2C | SLC6A2 1105/4885SLC6A4 856/4885NOS2 1209/4885 |
| US-20020169181-A1 | Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists | TACR2, CHRM3, TACR1 | SLC6A2 730/4885SLC6A4 921/4885NOS2 2753/4885 |
| US-20030100565-A1 | Method for the treatment or prevention of atopic dermatitis | TACR1, BDKRB1, CPA3 | SLC6A2 511/4885SLC6A4 897/4885NOS2 1034/4885 |
| US-20030212075-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND NK1-RECEPTOR ANTAGONISTS | TACR2, CHRM3, TACR1 | SLC6A2 730/4885SLC6A4 921/4885NOS2 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.